In addition, we have identified an association between low HER2 membrane staining and high CAV1 protein levels in gastric tumors (27), suggesting a potential role for CAV1 to be used as a complementary biomarker to improve the selection of gastric cancer patients who may benefit from treatment with anti-HER2–targeted therapies. Here, CAV1 is linked to gastric neoplasm.